Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Issues Earnings Results, Beats Estimates By $0.78 EPS

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUPGet Free Report) posted its quarterly earnings results on Friday. The company reported ($1.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.78, Zacks reports.

Neuphoria Therapeutics Inc. – Common Stock Price Performance

Shares of NEUP traded up $0.20 during midday trading on Friday, hitting $4.80. The stock had a trading volume of 49,914 shares, compared to its average volume of 1,079,359. Neuphoria Therapeutics Inc. – Common Stock has a 1 year low of $2.12 and a 1 year high of $15.96.

Analyst Ratings Changes

Separately, HC Wainwright boosted their target price on shares of Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, February 4th.

View Our Latest Research Report on Neuphoria Therapeutics Inc. – Common Stock

About Neuphoria Therapeutics Inc. – Common Stock

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Read More

Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.